Warning! GuruFocus detected
1 Severe warning sign
with ORGO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Organogenesis Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US68621F1021
Share Class Description:
ORGO: Class ACompare
Compare
Traded in other countries / regions
ORGO.USA2PQ.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2016-11-29Description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.13 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 2.75 | |||||
| Interest Coverage | 13.94 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 4.85 | |||||
| Beneish M-Score | -1.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1.5 | |||||
| 3-Year EBITDA Growth Rate | -43.1 | |||||
| 3-Year EPS without NRI Growth Rate | -43.7 | |||||
| 3-Year FCF Growth Rate | -48.2 | |||||
| 3-Year Book Growth Rate | 3.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 11.82 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.62 | |||||
| 9-Day RSI | 56.82 | |||||
| 14-Day RSI | 57.56 | |||||
| 3-1 Month Momentum % | 0.94 | |||||
| 6-1 Month Momentum % | 15.88 | |||||
| 12-1 Month Momentum % | 22.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 3.35 | |||||
| Cash Ratio | 1.75 | |||||
| Days Inventory | 85.83 | |||||
| Days Sales Outstanding | 75 | |||||
| Days Payable | 85.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.8 | |||||
| Shareholder Yield % | 8.1 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.99 | |||||
| Operating Margin % | 4.46 | |||||
| Net Margin % | 0.18 | |||||
| FCF Margin % | 0.87 | |||||
| ROE % | 0.29 | |||||
| ROA % | 0.19 | |||||
| ROIC % | -2.07 | |||||
| 3-Year ROIIC % | -401.15 | |||||
| ROC (Joel Greenblatt) % | -0.59 | |||||
| ROCE % | -0.33 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 91.2 | |||||
| PE Ratio without NRI | 41.68 | |||||
| PS Ratio | 1.32 | |||||
| PB Ratio | 2.31 | |||||
| Price-to-Tangible-Book | 2.75 | |||||
| Price-to-Free-Cash-Flow | 150.03 | |||||
| Price-to-Operating-Cash-Flow | 44.5 | |||||
| EV-to-EBIT | -548.06 | |||||
| EV-to-Forward-EBIT | 5.05 | |||||
| EV-to-EBITDA | 43.91 | |||||
| EV-to-Forward-EBITDA | 4.15 | |||||
| EV-to-Revenue | 1.44 | |||||
| EV-to-Forward-Revenue | 0.78 | |||||
| EV-to-FCF | 171.83 | |||||
| Price-to-GF-Value | 1.45 | |||||
| Price-to-Projected-FCF | 2.49 | |||||
| Price-to-Graham-Number | 2.25 | |||||
| Price-to-Net-Current-Asset-Value | 11.79 | |||||
| Price-to-Net-Cash | 26.86 | |||||
| Earnings Yield (Greenblatt) % | -0.18 | |||||
| FCF Yield % | 0.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ORGO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Organogenesis Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 482.043 | ||
| EPS (TTM) ($) | -0.02 | ||
| Beta | 1.38 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.53 | ||
| Volatility % | 89.27 | ||
| 14-Day RSI | 57.56 | ||
| 14-Day ATR ($) | 0.414937 | ||
| 20-Day SMA ($) | 5.058 | ||
| 12-1 Month Momentum % | 22.52 | ||
| 52-Week Range ($) | 2.165 - 6.71 | ||
| Shares Outstanding (Mil) | 126.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Organogenesis Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Organogenesis Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Organogenesis Holdings Inc Frequently Asked Questions
What is Organogenesis Holdings Inc(ORGO)'s stock price today?
The current price of ORGO is $4.84. The 52 week high of ORGO is $6.71 and 52 week low is $2.17.
When is next earnings date of Organogenesis Holdings Inc(ORGO)?
The next earnings date of Organogenesis Holdings Inc(ORGO) is 2025-05-09 Est..
Does Organogenesis Holdings Inc(ORGO) pay dividends? If so, how much?
Organogenesis Holdings Inc(ORGO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers